Expression of Keratin 19 Distinguishes Papillary Thyroid Carcinoma from Follicular Carcinoma and Follicular Thyroid Adenoma

1989 ◽  
Vol 92 (5) ◽  
pp. 654-658 ◽  
Author(s):  
Lodewijk J. D. M. Schelfhout ◽  
Goos N. P. Van Muijen ◽  
Gert Jan Fleuren
1998 ◽  
Vol 45 (1) ◽  
pp. 61-67 ◽  
Author(s):  
YOSHIHIKO SATO ◽  
AKIHIRO SAKURAI ◽  
TAKAHIDE MIYAMOTO ◽  
KUNIHIDE HIRAMATSU ◽  
MIYUKI KATAI ◽  
...  

2015 ◽  
Vol 14 (8) ◽  
pp. 3315-3321 ◽  
Author(s):  
Yanan Xu ◽  
Xiaojiao Zheng ◽  
Yunping Qiu ◽  
Wei Jia ◽  
Jiadong Wang ◽  
...  

2019 ◽  
Vol 133 (8) ◽  
pp. 696-699
Author(s):  
G Nakache ◽  
G Yahav ◽  
G H Siloni ◽  
I Barshack ◽  
E Alon ◽  
...  

AbstractObjectiveTo explore the use of fluorescence lifetime imaging microscopy in thyroid tissues, and to investigate how different thyroid lesions affect fluorescence lifetime.MethodFluorescence lifetime measurements were taken of fresh frozen thyroid surgical specimens stained with fluorescein isothiocyanate tagged anti-thyroglobulin monoclonal antibodies.ResultsThe mean fluorescence lifetime measurements in 12 patients – 3 with multinodular goitre, 4 with follicular adenoma, 4 with papillary thyroid carcinoma and 1 with follicular carcinoma – were 3.16 ns (range, 2.66–3.52 ns), 3.75 ns (range, 2.99–4.57 ns), 2.97 ns (range, 2.57–3.21 ns) and 3.61 ns, respectively. The fluorescence lifetime of follicular adenoma patients was higher than that of papillary thyroid carcinoma patients by 26 per cent (p = 0.058). The fluorescence lifetime in the follicular carcinoma patient was similar to the follicular adenoma group, but higher than in the papillary thyroid carcinoma group by 22 per cent (p = 0.01).ConclusionFluorescence lifetime measurements varied in different thyroid pathologies, possibly because of tissue-scale structural influences.


2016 ◽  
Vol 02 (01) ◽  
pp. 043-045
Author(s):  
Yasmin Momin ◽  
Sameer Ansari ◽  
Bharat Ghodke

AbstractSolid, encapsulated, follicular variant of papillary carcinoma of thyroid is termed as Lindsay tumor. Follicular carcinoma carries a worse prognosis than papillary thyroid carcinoma with higher incidence of hematogenous metastasis. Lindsay tumor being encapsulated follows an indolent course and has a better outcome. We present a rare case of Lindsay tumor in a 30 years adult male who presented with hoarseness of voice.


Thyroid ◽  
2003 ◽  
Vol 13 (3) ◽  
pp. 291-295 ◽  
Author(s):  
Chisato Tomoda ◽  
Ryoji Kushima ◽  
Eiji Takeuti ◽  
Ken-ichi Mukaisho ◽  
Takanori Hattori ◽  
...  

2021 ◽  
Vol 8 (26) ◽  
pp. 2288-2293
Author(s):  
Anuradha G. Patil ◽  
Saniya Jahan ◽  
Syed Mukhtar Mohiuddin

BACKGROUND Thyroid carcinoma is the most common endocrine malignancy. Galectin-3 has been implicated in malignant transformation and metastasis of cancer cells and it has received notable recognition for its usefulness as a diagnostic marker for thyroid cancer. We wanted to evaluate the expression of Galectin-3 on thyroid neoplasms, establish its diagnostic accuracy and also differentiate between benign and malignant thyroid lesions. METHODS A total of 54 thyroidectomy specimens were studied over a period of 3 years (2016 - 2019) which included 20 benign and 34 malignant thyroid neoplasms. Histopathologic evaluation of H & E stained sections was done and immunohistochemistry (IHC) staining for Galectin-3 was performed for all neoplasms with the polymeric method using lyophilized mouse monoclonal antibody. (Path n Situ) and grading based on intensity of Galectin-3 expression were noted. RESULTS Galectin-3 expression was significantly higher (P < 0.001) in malignant thyroid neoplasms in comparison to the benign neoplasms. Galectin-3 expression for malignant neoplasms showed sensitivity of 88.23 %, specificity of 95.0 %, positive predictive value (PPV) of 96.8 % and negative predictive value (NPV) of 82.6 %. Galectin-3 expression in Papillary thyroid carcinoma showed a sensitivity of 95.83 % and PPV of 88.2 %. While comparing the neoplasms showing follicular pattern, Galectin-3 expression was more in the malignant neoplasms (follicular carcinoma and follicular variant of papillary carcinoma thyroid) than benign neoplasms (follicular adenoma). CONCLUSIONS Galectin-3 is a useful marker in differentiating benign and malignant thyroid neoplasms. Galectin-3 is sensitive for Papillary thyroid carcinoma (PTC) and among the follicular patterned lesions, Galectin-3 is sensitive for follicular variant of papillary carcinoma and follicular carcinoma. Thus Galectin-3 protein expression evaluated using immunohistochemistry technique acts as an adjunctive ancillary technique in thyroid cancer diagnosis. KEYWORDS Galectin-3, Immunohistochemistry, Thyroid Carcinoma, Papillary Thyroid Carcinoma


2017 ◽  
Vol 42 (1) ◽  
pp. 21-27
Author(s):  
Mohammad Mosiur Rahman ◽  
Sultana Gulshan Banu ◽  
Ashim Ranjan Barua ◽  
Mohammed Kamal ◽  
Muhammod Nazmul Baqui ◽  
...  

A significant increase in incidence of papillary thyroid carcinoma (PTC) has been noticed in recent decades worldwide. This is due to advances in medical surveillance, increased use of ancillary tests, and a minor component due to over diagnosis of PTC. Follicular variant of papillary thyroid carcinoma (FVPTC) is the second most common variant of PTC and comprises about 23-41%. It is difficult to diagnose histologically when the distinctive nuclear features are either not well developed or present focally within the lesion. Several immunohistochemical markers (CD56, HMCK, GAL3, HBME-1 and CK19) either alone or combined in panels can be used to improve diagnostic accuracy. This study was aimed to differentiate FVPTC from other follicular patterned lesion of thyroid by histopathology and immunohistochemistry (IHC). A total of 50 histologically diagnosed cases of thyroid neoplasm were studied. The neoplastic cases included 40 cases of follicular variant papillary carcinoma (FVPC), 04 classic papillary carcinoma (PTC), 04 follicular carcinoma and 02 follicular adenoma. All cases were evaluated by IHC for the expression of CD56 and CK19 antibody. In case of FVPTC (n=40), 21 cases (52.5%) were CK19 positive and CD56 negative as expected. Both markers were found positive in 06 (15%) cases and CD56+ alone was found positive in 11 (27.5%) cases of FVPTC, and a finding that goes against the diagnosis of FVPTC. The histopathological slides of these cases were reviewed and findings were recorded. All cases (n=4) of classic PTC were CK19 positive and 03 (75%) cases were found CD56 negative. Diagnoses of thyroid follicular lesions are primarily based on histological and cytomorphological criteria. However, there was a subset of follicular patterned tumors like FVPTC which lack unequivocal features of malignancy. Immunohistochemistry can improve diagnostic accuracy but needs additional studies for controversial cases. It may be considered these lesions as differentiated tumor of uncertain malignant potential (WDT-UMP) to avoid the using term carcinoma. Additional studies are needed for establishing more precise morphologic criteria and for identifying useful markers for differentiating benign from borderline or malignant thyroid lesions.


2021 ◽  
Vol 67 (2) ◽  
pp. 287-292
Author(s):  
Andrew Golubtsov ◽  
Alexandr Aladin

The article presents a clinical observation and surgical treatment of a patient with papillary thyroid carcinoma, thyroid adenoma and a giant dermoid cyst of the neck.


Sign in / Sign up

Export Citation Format

Share Document